However, our findings suggest that lower-risk MDS patients may survive with small TP53 subclones for several years, unlike those with higher-risk MDS and leukemias as described in some studies [17, 19, 20, and 27]. The gene discussed is TP53; the disease is myelodysplastic syndrome.